These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20306913)

  • 21. Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study.
    Janić M; Lunder M; France Štiglic A; Jerin A; Skitek M; Černe D; Marc J; Drevenšek G; Šabovič M
    Vascul Pharmacol; 2017 Dec; 99():45-52. PubMed ID: 28951255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of Resveratrol and Octreotide on peritoneal adhesions in a rat model.
    Üreyen O; Üstuner MA; Argon A; Özbilgin M; Egeli T; Ìlhan E; Vardar E; Ünek T; Yildirim M; Erkan N
    Malays J Pathol; 2018 Aug; 40(2):153-160. PubMed ID: 30173233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of resveratrol on surgery-induced peritoneal adhesions in an experimental model.
    Sogutlu G; Karabulut AB; Ara C; Cinpolat O; Isik B; Piskin T; Celik O
    Cell Biochem Funct; 2007; 25(2):217-20. PubMed ID: 16615042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.
    Bandoh T; Sato EF; Mitani H; Nakashima A; Hoshi K; Inoue M
    Biol Pharm Bull; 2003 Jun; 26(6):818-22. PubMed ID: 12808293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation.
    Fischetti F; Carretta R; Borotto G; Durigutto P; Bulla R; Meroni PL; Tedesco F
    Clin Exp Immunol; 2004 Feb; 135(2):186-93. PubMed ID: 14738444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adenovirus-mediated overexpression of human tissue plasminogen activator prevents peritoneal adhesion formation/reformation in rats.
    Atta HM; Al-Hendy A; El-Rehany MA; Dewerchin M; Abdel Raheim SR; Abdel Ghany H; Fouad R
    Surgery; 2009 Jul; 146(1):12-7. PubMed ID: 19541005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preventing intraperitoneal adhesions with vitamin E and sodium hyaluronate/carboxymethylcellulose: a comparative study in rats.
    Corrales F; Corrales M; Schirmer CC
    Acta Cir Bras; 2008; 23(1):36-41. PubMed ID: 18278391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced P-selectin in hearts pretreated with fluvastatin: a novel benefit for patients undergoing open heart surgery.
    Berkan O; Katrancioglu N; Ozker E; Ozerdem G; Bakici Z; Yilmaz MB
    Thorac Cardiovasc Surg; 2009 Mar; 57(2):91-5. PubMed ID: 19241310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphatidylcholine and intraperitoneal adhesions.
    Kappas AM; Fatouros M; Siamopoulos K; Mylonakis M; Cassioumis D
    Perit Dial Int; 1993; 13 Suppl 2():S77-8. PubMed ID: 8399676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunction.
    Westphal S; Abletshauser C; Luley C
    Coron Artery Dis; 2009 Jan; 20(1):81-5. PubMed ID: 19060628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melatonin prevents peritoneal adhesions in rats.
    Ersoz N; Ozler M; Altinel O; Sadir S; Ozerhan IH; Uysal B; Topal T; Guven A; Korkmaz A
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1763-7. PubMed ID: 19686418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit.
    Tse FL; Labbadia D
    Biopharm Drug Dispos; 1992 May; 13(4):285-94. PubMed ID: 1600114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Efficacy of an Ultrapure Alginate Gel in Reducing Adhesion Formation in a Rat Model of Blood Contamination.
    Hol JC; Strik C; Chaturvedi AA; Lomme RMLM; van Goor H; Stommel MWJ; Ten Broek RPG
    J Surg Res; 2019 Sep; 241():271-276. PubMed ID: 31035142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.
    Fauler G; Abletshauser C; Erwa W; Löser R; Witschital K; März W
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):328-34. PubMed ID: 17595890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An evaluation of low molecular weight heparin and hyperbaric oxygen treatment in the prevention of intra-abdominal adhesions and wound healing.
    Arikan S; Adas G; Barut G; Toklu AS; Kocakusak A; Uzun H; Kemik O; Daduk Y; Aydin S; Purisa S
    Am J Surg; 2005 Feb; 189(2):155-60. PubMed ID: 15720982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of postoperative peritoneal adhesions by administration of estrogen.
    Bozkurt S; Yuzbasioglu MF; Bulbuloglu E; Gul M; Kale IT
    J Invest Surg; 2009; 22(4):263-7. PubMed ID: 19842901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
    Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
    Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histological Analysis of Intra-Abdominal Adhesions Treated with Sodium Hyaluronate and Carboxymethylcellulose Gel.
    Montalvo-Javé EE; Mendoza-Barrera GE; García-Pineda MA; Jaime Limón ÁR; Montalvo-Arenas C; Castell Rodríguez AE; Tapia Jurado J
    J Invest Surg; 2016; 29(2):80-7. PubMed ID: 26375456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of intra-abdominal administration of ligustrazine nanoparticles nano spray on postoperative peritoneal adhesion in rat model.
    Yan S; Yue YZ; Zeng L; Yue J; Li WL; Mao CQ; Yang L
    J Obstet Gynaecol Res; 2015 Dec; 41(12):1942-50. PubMed ID: 26419644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.